Core/shell structure platform for immunotherapy
US11382964B2 · kind B2 · utility
0Cited by
0References
30Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 26, 2018 |
| Grant date | Jul 12, 2022 |
| Priority date | — |
| Expiry date | Dec 20, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55555
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are biocompatible core/shell compositions suitable for the delivery of populations of mRNA molecules to mammalian cells. The disclosed core-shell structured multicomponent compositions are optimized for the delivery of mRNAs encoding one or more cancer- or tumor-specific antigens to a population of antigen presenting cells, including, for example, human dendritic cells, macrophages and B cells. Also disclosed are methods for use of these compositions as therapeutic cancer vaccines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.